Aktiesnakken — Februar 2011
-
15% er sku lidt af en stake
-
Novo Nordisks diabetes 2-middel Victoza vil have et konkurrencemæssigt overtag i forhold til danske Zealand Pharmas lægemiddelkandidat i samme medicinklasse, Lixisenatide.
Det vurderer analytiker i det schweiziske børshus Helvea, Karl Heinz Koch, de -
tror det kom bag på de fleste
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
